Yes, semaglutide can cause headaches. Most people in the weight-management trials did not report them, though, and a headache after a shot doesn't reveal its cause. Changes in eating, drinking, or caffeine can matter too. Sudden severe pain or a new vision change needs urgent attention.
Does semaglutide cause headaches in trials?
About 14 in 100 adults reported headache with Wegovy's 2.4 mg injection, compared with 10 in 100 receiving placebo, an inactive treatment. That's four additional people per 100, rather than everyone on the medication.
As of September 10, 2026, the day this article was written, the Wegovy prescribing information on DailyMed, marked “Revised: 6/2026,” still lists headache among common side effects. Its pooled adult trials and the original STEP 1 trial report slightly different figures:
| Source | Semaglutide group | Placebo group |
|---|---|---|
| Wegovy label, pooled adult 2.4 mg injection trials | 14% | 10% |
| STEP 1, 68-week trial | 15.2%: 198 of 1,306 adults | 12.2%: 80 of 655 adults |
The STEP 1 figures come from Table 3 of Wilding and colleagues' paper in the New England Journal of Medicine, 2021. That study enrolled adults with overweight or obesity without diabetes. The label combines several trials, so its percentages aren't interchangeable with this one study. Our STEP 1 results guide covers the broader findings.
The Ozempic prescribing information, marked “Revised: 5/2026” in the same writing-day check, has no headache row in its table of common side effects. It does list headache in reports received after marketing, where frequency cannot be calculated reliably. An absent table row doesn't mean an impossible side effect.
Why a headache might follow a shot
The timing is useful information, but it isn't a diagnosis. These are possibilities a provider considers, rather than explanations the trials established for every headache.
Fluid loss. Nausea can make drinking less appealing, while vomiting or diarrhea can remove fluid. Dehydration, meaning the body has too little fluid, can cause headache alongside thirst, a dry mouth, and darker urine. MedlinePlus describes those signs. The semaglutide labels also warn that substantial fluid loss can affect the kidneys.
Eating less. Appetite changes can turn a smaller meal into a skipped meal. The International Headache Society recognizes headache caused by fasting, which can happen without low blood sugar. “I haven't eaten” and “my blood sugar is dangerously low” aren't the same finding.
Other diabetes medicines. Hypoglycemia means low blood sugar. The Ozempic label lists headache among its possible symptoms and identifies greater risk with insulin or sulfonylureas, diabetes medicines that make the pancreas release insulin. Sweating, shaking, or confusion makes that medication history especially relevant.
Less caffeine. As of September 10, 2026, the day this article was written, a Scientific Reports analysis published May 22, 2026 adds evidence that caffeine withdrawal can cause headaches. In the 100-person CRAVE trial, participants had more headaches on days assigned to avoid caffeine. This wasn't a semaglutide study; it supports asking whether a person's coffee routine changed, not prescribing coffee as a remedy.
Stomach symptoms often cluster around dose increases. The headache tables don't establish a usual headache duration or prove that most headaches come from dehydration rather than a direct drug effect. The wider semaglutide side-effects guide covers the digestive symptoms.
Would tirzepatide avoid the headache?
Switching doesn't come with that assurance. Tirzepatide is another prescription weight-management medicine a provider might consider when semaglutide is difficult to tolerate.
In SURMOUNT-5, a trial of 751 adults published in the New England Journal of Medicine in 2025, stomach and bowel symptoms were common with both medicines, especially while doses increased. It wasn't a trial of switching people because of headaches. Those results cannot establish that tirzepatide will solve a semaglutide headache; the symptom's cause still matters.
Semaglutide and migraine: what the studies found
Migraine is a recurring headache disorder that can also bring nausea and sensitivity to light. Research into these medicines and migraine is interesting, but it answers a different question from whether an individual can develop a headache after starting treatment.
As of September 10, 2026, the day this article was written, an August 5, 2026 study in The Journal of Headache and Pain has followed pharmacy records for 189,392 Danish adults starting weight-management semaglutide. At 12 months, the amount of triptans dispensed—medicines used during migraine attacks—was 7% below the amount predicted from earlier trends. This measured medication dispensing, not headache days, and cannot prove semaglutide caused the change.
An earlier pilot by Braca and colleagues, first published June 17, 2025, in Headache, studied liraglutide, a different medicine in the GLP-1 family, which mimics a natural appetite and blood-sugar hormone. Among 31 adults with obesity and frequent migraine, average monthly headache days fell from 19.8 to 10.7 over 12 weeks.
That pilot was open-label, meaning everyone knew which treatment they received, with no placebo group. It cannot establish a migraine benefit for semaglutide or for a compounded preparation. Neither study makes a new or worsening headache something to dismiss.
When a headache needs urgent care
A sudden, explosive headache, the worst headache someone has experienced, or headache with new vision changes, weakness, confusion, or trouble speaking warrants emergency care. Fever with a stiff neck is another warning sign. These are general headache danger signs, regardless of medication use.
The semaglutide safety finding called NAION concerns damage to the nerve carrying vision from the eye; sudden sight loss or rapidly worsening eyesight needs urgent assessment, even without headache.
Ongoing vomiting, inability to keep fluids down, or very little urine also calls for prompt medical assessment. An online follow-up message isn't a substitute for emergency care.
What a provider asks about the headache
A useful review starts with what changed: when treatment began, when the dose changed, how soon the pain appeared, how long it lasted, and whether it resembles previous headaches. A provider also asks about food and fluid intake, caffeine, other medicines, and any blood-sugar readings available.
There is no need to guess the mechanism before describing the problem. The prescriber decides whether the pattern calls for an examination, testing, a dose change, or a different treatment. The actual dose remains the prescriber's decision.
Where compounded semaglutide fits
Through Promise, semaglutide is dispensed as a compounded medication, prepared by a pharmacy for a prescription, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.
As of September 10, 2026, the day this article was written, FDA's compounding guidance explains that these preparations do not undergo its safety, effectiveness, and quality review before marketing. The brand-trial headache rates cannot be assumed to be exact rates for a compounded formulation. A licensed provider may still prescribe a compounded formulation where appropriate; that decision is between the patient and the doctor, within applicable compounding requirements.
At Promise, a licensed U.S. provider reviews every request; not everyone qualifies. Follow-up gives the prescriber a chance to assess a headache in the context of the whole treatment, including whether continuing it makes sense.